MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 30, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter 2020 financial results after
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 7, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported
MONROVIA, Calif. --(BUSINESS WIRE)--May 13, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief executive
-- XmAb20717 generally well-tolerated and a confirmed complete response (CR) observed at highest dose level tested -- -- Robust, dose-dependent immune activation consistent with inhibition of both PD-1 and CTLA-4 checkpoints -- -- Further dose-escalation and expansion cohorts continue to enroll
MONROVIA, Calif. --(BUSINESS WIRE)--May 15, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical data on three XmAb ® 2+1
MONROVIA, Calif. --(BUSINESS WIRE)--May 26, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief executive
MONROVIA, Calif. --(BUSINESS WIRE)--Jun. 22, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new preclinical data from three XmAb ® 2+1
MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 8, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc.
MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 28, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release second quarter 2020 financial results
-- Monjuvi is a new treatment in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) -- -- Tafasitamab-cxix was created at Xencor and is the second product with Xencor's XmAb ® technology to be approved by the FDA -- -- Xencor to
